J. Isaacs

D. Green, R. Schulte‐Hermann, D. McConkey, 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Biological significance of measurable androgen levels in the rat ventral prostate following castration

N. Kyprianou, J. Isaacs, 1987, The Prostate.

Quantal relationship between prostatic dihydrotestosterone and prostatic cell content: Critical threshold concept

N. Kyprianou, J. Isaacs, 1987, The Prostate.

Prostatic structure and function in relation to the etiology of prostatic cancer

J. Isaacs, 1983, The Prostate.

Expression of homeobox gene‐GBX2 in human prostatic cancer cells

J. Isaacs, A. Gao, 1996, The Prostate.

CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13.

J. Isaacs, A. Gao, W. Lou, 1997, Cancer research.

Down-regulation of homeobox gene GBX2 expression inhibits human prostate cancer clonogenic ability and tumorigenicity.

J. Isaacs, A. Gao, W. Lou, 1998, Cancer research.

Suppression of the tumorigenicity of prostatic cancer cells by gene(s) located on human chromosome 19p13.1‐13.2

J. Barrett, J. Isaacs, S. Denmeade, 1999, The Prostate.

Prostate cancer androgen receptor activity dictates efficacy of Bipolar Androgen Therapy

Elizabeth A. Thompson, J. Luo, Jun Luo, 2022, medRxiv.

Molecular characterization of the commonly used human androgen receptor expression vector, pSG5‐AR

J. Isaacs, Chawnshang Chang, I. Litvinov, 2004, The Prostate.

Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death.

N. Kyprianou, J. Isaacs, 1989, Molecular endocrinology.

Suppression of mutant androgen receptors by flutamide

K. Nishikawa, J. Isaacs, J. Ishioka, 2009, International journal of urology : official journal of the Japanese Urological Association.

Effects of steroidal and non‐steroidal antiandrogens on wild‐type and mutant androgen receptors

K. Kihara, J. Isaacs, J. Ishioka, 2007, The Prostate.

Programmed cell death in an estrogen-independent human breast cancer cell line, MDA-MB-468.

N. Davidson, J. Isaacs, D. Armstrong, 1992, Cancer research.

Activation of programmed cell death in the rat ventral prostate after castration.

N. Kyprianou, J. Isaacs, 1988, Endocrinology.

Concentration of enzymatically active prostate‐specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models

D. Chan, L. Sokoll, J. Isaacs, 2001, The Prostate.

The relationship of cellular structure and function: the matrix system.

W. Isaacs, D. S. Coffey, J. Isaacs, 1981, Progress in clinical and biological research.

Synergistic enhancement of the efficacy of the bioreductively activated alkylating agent RSU-1164 in the treatment of prostatic cancer by photodynamic therapy.

J. M. Henry, J. Isaacs, J. M. Henry, 1989, The Journal of urology.

Concepts in prostatic cancer biology: Dunning R-3327 H, HI, and AT tumors.

D. S. Coffey, J. Isaacs, W. Scott, 1980, Progress in clinical and biological research.

CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

A. Klein-Szanto, P. Casellas, P. Dobrzanski, 2003, Cancer research.

Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents.

J. Isaacs, I. Joseph, John T. Isaacs, 1998, Journal of the National Cancer Institute.

Stimulation of human prostatic carcinoma tumor growth in athymic mice and control of migration in culture by extracellular matrix

A. Passaniti, H. Kleinman, J. Isaacs, 1992, International journal of cancer.

Enhancement of the T-cell armamentarium as a cell-based therapy for prostate cancer.

C. Drake, J. Isaacs, W. Brennen, 2014, Cancer research.

Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen.

H. Lilja, J. Malm, J. Isaacs, 1997, Cancer research.

Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention

J. Isaacs, 1990, The Prostate. Supplement.

The role of prostate‐specific antigen in the clinical evaluation of prostatic disease

J. Isaacs, S. Denmeade, John T. Isaacs, 2004, BJU international.

Mesenchymal stem cell infiltration during neoplastic transformation of the human prostate

A. D. De Marzo, J. Isaacs, A. Meeker, 2017, Oncotarget.

Polo-like kinase-1 Inhibitors and the Antiandrogen Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling

M. Erlander, M. Yaffe, Jun Luo, 2022, bioRxiv.

Denmeade Endothelial Cell Prodrug for Cancer Therapy Activated Tumor − Engineering a Prostate-Specific Membrane Antigen

S. Christensen, G. Wilding, P. Nissen, 2012 .

Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment.

Jun Luo, T. Leanderson, J. Isaacs, 2013, Cancer research.

Therapeutics , Targets , and Chemical Biology Tasquinimod Is an Allosteric Modulator of HDAC 4 Survival Signalingwithin theCompromisedCancerMicroenvironment

Jun Luo, T. Leanderson, J. Isaacs, 2013 .

The role of androgen in the regulation of programmed cell death/apoptosis in normal and malignant prostatic tissue.

Y. Furuya, J. Isaacs, R. Berges, 1994, Seminars in cancer biology.

Enhanced GBX2 expression stimulates growth of human prostate cancer cells via transcriptional up-regulation of the interleukin 6 gene.

J. Isaacs, A. Gao, W. Lou, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts

T. DeWeese, Haoming Zhou, J. Isaacs, 2012, The Prostate.

The quinoline‐3‐carboxamide anti‐angiogenic agent, tasquinimod, enhances the anti‐prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts

J. Isaacs, S. Dalrymple, Robin E. Becker, 2007, The Prostate.

Prostate‐specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate‐targeted PSA/KLK2 double transgenic mice

A. D. De Marzo, Simon A. Williams, J. Isaacs, 2010, The Prostate.

Prevention of Prostatic Carcinogenesis — Is it Realistic?

J. Isaacs, 1988 .

Localization of metastasis suppressor gene(s) for prostatic cancer to the short arm of human chromosome 11.

M. Oshimura, W. Isaacs, J. Barrett, 1992, Cancer research.

Rational basis for Trk inhibition therapy for prostate cancer

A. Weeraratna, A. DeMarzo, J. Isaacs, 2000, The Prostate.

Biology and therapy of prostatic cancer.

J. Isaacs, H. Schulze, 1986, Cancer surveys.

Aggressiveness of Prostate Cancer

J. Isaacs, 2007 .

Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer.

J. Isaacs, 1997, The American journal of pathology.

Nonimmunosuppressant immunophilin ligand GPI-1046 does not promote in vitro growth of prostate cancer cells.

J. Isaacs, A. Burnett, M. Kramer, 2005, Urology.

Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation.

N. Kyprianou, J. Isaacs, H. English, 1990, Cancer research.

Relationship between metastatic ability and H-ras oncogene expression in rat mammary cancer cells transfected with the v-H-ras oncogene.

N. Kyprianou, J. Isaacs, 1990, Cancer research.

Heparin binding affinity of rat prostatic growth factor in normal and cancerous prostates: partial purification and characterization of rat prostatic growth factor in the Dunning tumor.

S. Matsui, J. Isaacs, A. Sandberg, 1987, Cancer research.

A history of prostate cancer treatment

J. Isaacs, S. Denmeade, Samuel R. Denmeade, 2002, Nature Reviews Cancer.

Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells.

S. Christensen, C. Olsen, J. Isaacs, 2001, Journal of medicinal chemistry.

Enzymatic activation of prodrugs by prostate-specific antigen: targeted therapy for metastatic prostate cancer.

J. Isaacs, S. Denmeade, 1998, The cancer journal from Scientific American.

Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss.

W. Isaacs, J. Barrett, J. Schalken, 1996, Cancer research.

Retinoic acid binding protein in normal and neoplastic rat prostate

J. Isaacs, E. Arnold, M. Gesell, 1982, The Prostate.

Clinical evidence for and implications of the multistep development of prostate cancer.

S. Piantadosi, H. Carter, J. Isaacs, 1990, The Journal of urology.

Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling?

A. D. De Marzo, J. Isaacs, I. Litvinov, 2003, The Journal of clinical endocrinology and metabolism.

Prostate cancer: where are we and where are we going?

J. Isaacs, S. Denmeade, 1997, British journal of urology.

alpha1-ADRENOCEPTOR ANTAGONISTS TERAZOSIN AND DOXAZOSIN INDUCE PROSTATE APOPTOSIS WITHOUT AFFECTING CELL PROLIFERATION IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA

A. Borkowski, A. Partin, N. Kyprianou, 1999 .

"Thymineless" death in androgen-independent prostatic cancer cells.

N. Kyprianou, J. Isaacs, 1989, Biochemical and biophysical research communications.

New biochemical methods to determine androgen sensitivity of prostatic cancer: the relative enzymatic index (REI).

D. S. Coffey, J. Isaacs, W. Scott, 1979, Progress in clinical and biological research.

Antagonistic effect of androgen on prostatic cell death

J. Isaacs, 1984 .

Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.

J. Isaacs, I. Joseph, 1997, Cancer research.

Suppression of metastasis of rat prostatic cancer by introducing human chromosome 8.

Y. Nakamura, M. Oshimura, M. Emi, 1994, Cancer research.

Prostate stem cells and benign prostatic hyperplasia

J. Isaacs, 2008, The Prostate.

Role of calcium in the programmed death of rat prostatic glandular cells

J. Isaacs, P. Martikainen, 1990, The Prostate.

Experimental intravesical therapy for superficial transitional cell carcinoma in a rat bladder tumor model.

C. Brendler, G. Steinberg, J. Isaacs, 1991, The Journal of urology.

Activation of programmed cell death by recombinant human tumor necrosis factor plus topoisomerase II-targeted drugs in L929 tumor cells.

N. Kyprianou, J. Isaacs, R. Alexander, 1991, Journal of the National Cancer Institute.

A supramicromolar elevation of intracellular free calcium ([Ca2+]i) is consistently required to induce the execution phase of apoptosis

B. Tombal, J. Gillis, J. Isaacs, 2002, Cell Death and Differentiation.

Tumor necrosis factor enhances the in vitro and in vivo efficacy of chemotherapeutic drugs targeted at DNA topoisomerase II in the treatment of murine bladder cancer.

D. S. Coffey, J. Isaacs, R. Alexander, 1987, The Journal of urology.

2‐fluoro‐5‐maleimidobenzoic acid‐linked albumin drug (MAD) delivery for selective systemic targeting of metastatic prostate cancer

J. Isaacs, Emmanuel S. Akinboye, O. Rogers, 2018, The Prostate.

Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.

H. Lilja, E. Garrett, J. Isaacs, 2003, Journal of the National Cancer Institute.

Estramustine binding protein (EMBP) in rat R3327 dunning tumors: Partial characterization and effect of hormonal withdrawal, hormonal replacement, and cytotoxic treatment on its expression

J. Isaacs, P. Björk, B. Hartley‐åsp, 1991, The Prostate.

Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models

L. Sokoll, J. Isaacs, D. Rosen, 2003, The Prostate.

Effect of Transforming Growth Factor-β1 on Proliferation and Death of Rat Prostatic Cells*

N. Kyprianou, J. Isaacs, P. Martikainen, 1990 .

Differential effects of growth factor antagonists on neoplastic and normal prostatic cells

W. Isaacs, J. Isaacs, R. Morton, 1990, The Prostate.

Low p16INK4a Expression in Early Passage Human Prostate Basal Epithelial Cells Enables Immortalization by Telomerase Expression Alone

J. Isaacs, A. Meeker, L. Antony, 2017, The Prostate.

Common characteristics of human and canine benign prostatic hyperplasia.

J. Isaacs, 1984, Progress in clinical and biological research.

A critical review of the concept of total androgen ablation in the treatment of prostate cancer.

D. S. Coffey, J. Isaacs, H. Schulze, 1987, Progress in clinical and biological research.

Genetic control of resistance to chemically induced mammary adenocarcinogenesis in the rat.

J. Isaacs, 1986, Cancer research.

Advances in Brief Epidermal Growth Factor-mediated Apoptosis of MDA-MB-468 Human Breast Cancer Cells 1

Yvonne, S. Kaufmann, Y. Furuya, 2006 .

Programmed Cell Death during Regression of PC-82 Human Prostate Cancer following Androgen Ablation 1

N. Kyprianou, J. Isaacs, H. English, 2006 .

The Prostate 69 : 1724 ^ 1729 ( 2009 ) TissueCultureMedia SupplementedWith 10 % Fetal Calf SerumContains aCastrate Levelof Testosterone

J. Isaacs, J. Sedelaar, J. Sedelaar, 2009 .

Pharmacologic Basis for the Enhanced Efficacy of Dutasteride against Prostatic Cancers

J. Isaacs, S. Denmeade, S. Dalrymple, 2006, Clinical Cancer Research.

Enhanced GBX 2 Expression Stimulates Growth of Human Prostate Cancer Cells via Transcriptional Up-Regulation of the Interleukin 6 Gene 1

J. Isaacs, A. Gao, W. Lou, 2000 .

Concise Review: Mesenchymal Stem Cell‐Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise

J. Isaacs, S. Denmeade, D. Thorek, 2018, Stem cells translational medicine.

Down modulation of fibronectin messenger RNA in metastasizing rat prostatic cancer cells revealed by differential hybridization analysis.

J. Schalken, W. V. D. Van de Ven, J. Isaacs, 1988, Cancer research.

Metastasis suppressor genes for prostate cancer

M. Oshimura, J. Barrett, J. Isaacs, 1996, The Prostate. Supplement.

Cytotoxic phenylpropanoids and an additional thapsigargin analogue isolated from Thapsia garganica.

L. Tran, Ming Chen, L. Zhai, 2006, Phytochemistry.

Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)‐activated thapsigargin prodrug

H. Lilja, J. Isaacs, D. Rosen, 2006, The Prostate.

Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)‐activated thapsigargin prodrug

H. Lilja, J. Isaacs, D. Rosen, 2006, The Prostate.

Assessment and validation of a microinjection method for kinetic analysis of [Ca2+]i in individual cells undergoing apoptosis.

B. Tombal, J. Isaacs, S. Denmeade, 1999, Cell calcium.

Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen.

H. Lilja, J. Isaacs, A. Schally, 1998, Cancer research.

Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic cancer cells induced by thapsigargin

J. Isaacs, S. Denmeade, L. Cisek, 1997, The Prostate.

Prostatic involution in rats induced by a novel 5 alpha-reductase inhibitor, SK&F 105657: role for testosterone in the androgenic response.

J. Isaacs, R. Johnson, G. Rhodes, 1992, Endocrinology.

Association of glyceraldehyde-3-phosphate dehydrogenase expression with cell motility and metastatic potential of rat prostatic adenocarcinoma.

A. Partin, D. S. Coffey, J. Schalken, 1993, Cancer research.

Molecular advances in prostate cancer.

W. Isaacs, J. Isaacs, J. Dong, 1997, Current opinion in oncology.

Of mice and men‐warning: Intact versus castrated adult male mice as xenograft hosts are equivalent to hypogonadal versus abiraterone treated aging human males, respectively

J. Isaacs, S. Dalrymple, J. Sedelaar, 2013, The Prostate.

OfMice andMen-Warning : IntactVersusCastratedAdult MaleMice asXenograftHostsAre Equivalentto

J. Isaacs, S. Dalrymple, J. Sedelaar, 2013 .

An organ culture system for the study of programmed cell death in the rat ventral prostate.

J. Isaacs, P. Martikainen, 1990, Endocrinology.

Antagonistic effect of androgen on prostatic cell death

J. Isaacs, 1985, The Prostate.

Establishment and characterization of seven dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers

W. Isaacs, J. Isaacs, W. Feitz, 1987, The Prostate.

Models for development of nonreceptor methods for distinguishing androgen-sensitive and -insensitive prostatic tumors.

W. Isaacs, D. S. Coffey, J. Isaacs, 1979, Cancer research.

Human Breast Cancer following Estrogen Ablation Programmed Cell Death during Regression of the MCF-7 Updated Version

Kyprianou, Natasha, N. Davidson, 2006 .

Programmed Cell Death during Regression of the MCF-7 Human Breast Cancer following Estrogen Ablation 1

Kyprianou, Natasha, N. Davidson, 2006 .

Induction of Programmed Death/Apoptosis in Androgen‐dependent Mouse Mammary Tumor Cell Line (Shionogi Carcinoma 115) by Androgen Withdrawal

Y. Furuya, J. Isaacs, J. Shimazaki, 1995, Japanese journal of cancer research : Gann.

Proliferation‐dependent vs. independent programmed cell death of prostatic cancer cells involves distinct gene regulation

Y. Furuya, J. Isaacs, 1994, The Prostate.

Differential gene regulation during programmed death (apoptosis) versus proliferation of prostatic glandular cells induced by androgen manipulation.

Y. Furuya, J. Isaacs, 1993, Endocrinology.

Activation of a Ca2+−Mg2+‐dependent endonuclease as an early event in castration‐induced prostatic cell death

N. Kyprianou, J. Isaacs, H. English, 1988, The Prostate.

Growth Factors Affecting Normal and Malignant Prostatic Cells

W. Isaacs, J. Isaacs, P. Martikainen, 1991 .

Isolation of a 41 kilodalton cytosol protein from the dunning rat prostatic adenocarcinoma: Characterization as depolymerized actin isomers

S. Matsui, J. Isaacs, A. Sandberg, 1987, The Prostate.

Androgen regulation of programmed death of normal and malignant prostatic cells.

N. Kyprianou, J. Isaacs, R. Berges, 1992, Journal of andrology.

Therapeutic Approaches to Activating Programmed Cell Death of Androgen-Independent Prostatic Cancer Cells

N. Kyprianou, J. Isaacs, P. Martikainen, 1991 .

Animal models of the hormone-sensitive and -insensitive prostatic adenocarcinomas, Dunning R-3327-H, R-3327-HI, and R-3327-AT.

D. S. Coffey, J. Isaacs, W. Heston, 1978, Cancer research.

PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor

J. Isaacs, Linzhao Cheng, I. Litvinov, 2006, The Prostate.

Defining regulatory elements in the human KAI1 (CD 82) metastasis suppressor gene

J. Barrett, J. C. Barrett, J. Isaacs, 2003, The Prostate.

The characterization of a newly identified, highly metastatic variety of Dunning R 3327 rat prostatic adenocarcinoma system: the MAT LyLu tumor.

D. S. Coffey, J. Isaacs, G. Yu, 1981, Investigative urology.

The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer

J. Isaacs, 1984, The Prostate.

Epidermal growth factor-mediated apoptosis of MDA-MB-468 human breast cancer cells.

N. Davidson, S. Kaufmann, Y. Furuya, 1994, Cancer research.

Discrimination between normal, hyperplastic and malignant human prostatic tissues by enzymatic profiles.

C. Brendler, J. Isaacs, A. Follansbee, 1985, The Journal of urology.

Response of rat and human prostatic cancers to the novel 5α‐reductase inhibitor, SK&F 105657

J. Isaacs, Randall K. Johnson, J. Lamb, 1992 .

Programmed Cell Death during Regression of PC-82 Human Prostate Cancer following Androgen Ablation1

N. Kyprianou, J. Isaacs, H. English, 2006 .

Unusual androgen sensitivity of the androgen-independent Dunning R-3327-G rat prostatic adenocarcinoma: androgen effect on tumor cell loss.

J. Isaacs, J. Humphries, J. Humphries, 1982, Cancer research.

Metastasis suppressor gene(s) for rat prostate cancer on the long arm of human chromosome 7

M. Oshimura, J. Barrett, J. Isaacs, 1999, Genes, chromosomes & cancer.

Breast Cancer Cell Line , MDA-MB-468 Programmed Cell Death in an Estrogen-independent Human Updated

J. Isaacs, D. Armstrong, Y. Ottaviano, 2006 .

Programmed Cell Death in an Estrogen-independent Human Breast Cancer Cell Line , MDA-MB-4681

N. Davidson, J. Isaacs, D. Armstrong, 2006 .

Role of programmed cell death in carcinogenesis.

J. Isaacs, 1993, Environmental health perspectives.

Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents.

J. Isaacs, I. Joseph, J. Vukanović, 1996, Cancer research.

The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers.

J. Isaacs, T. Ichikawa, J. Lamb, 1992, Cancer research.

Relationship between tumor size and the curability of metastatic prostatic cancer by surgery alone or in combination with adjuvant chemotherapy.

J. Isaacs, J. M. Henry, 1988, The Journal of urology.

Identification of ABR‐215050 as lead second generation quinoline‐3‐carboxamide anti‐angiogenic agent for the treatment of prostate cancer

D. Qian, J. B. Garrison, T. Leanderson, 2006, The Prostate.

Advances in Brief Enzymatic Activation of a Doxorubicin-Peptide Prodrug by Prostate-Specific Antigen 1

H. Lilja, Samuel, J. Isaacs, 2006 .

Molecular characterization of an improved vector for evaluation of the tumor suppressor versus oncogene abilities of the androgen receptor

J. Isaacs, I. Litvinov, L. Antony, 2004, The Prostate.

In vitro culturing and characteristics of transit amplifying epithelial cells from human prostate tissue

J. Isaacs, A. Uzgare, Yi Xu, 2004, Journal of cellular biochemistry.

A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer.

J. Isaacs, S. Denmeade, Wei Yao, 2002, Bioorganic & medicinal chemistry letters.

Mixed lineage kinase (MLK) family members are not involved in androgen regulation of prostatic proliferation or apoptosis *

J. Isaacs, J. Gao, Jin Gao, 2001, The Prostate.

Modified synthesis and antiangiogenic activity of linomide.

J. Isaacs, R. Pili, S. R. Khan, 2001, Bioorganic & medicinal chemistry letters.

Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide.

J. Isaacs, J. Vukanović, 1995, Cancer research.

Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation.

T. Jacks, Y. Furuya, J. Isaacs, 1993, Proceedings of the National Academy of Sciences of the United States of America.

Experimental and theoretical basis for hormonal treatment of prostatic cancer.

H. Carter, J. Isaacs, 1988, Seminars in urology.

Development of androgen resistance in prostatic cancer.

D. S. Coffey, J. Isaacs, H. Schulze, 1987, Progress in clinical and biological research.

Hormonally responsive versus unresponsive progression of prostatic cancer to antiandrogen therapy as studied with the Dunning R-3327-AT and -G rat adenocarcinomas.

J. Isaacs, 1982, Cancer research.

Prostate tumor biology and cell kinetics--theory.

D. S. Coffey, J. Isaacs, 1981, Urology.

Development of a high‐efficiency method for gene marking of Dunning prostate cancer cell lines with the enzyme β‐galactosidase

J. Simons, J. Isaacs, C. Rinker-Schaeffer, 1996 .

Activation of latent protease function of pro‐hk2, but not pro‐PSA, involves autoprocessing

H. Lilja, J. Isaacs, S. Denmeade, 2001, The Prostate.

Effectiveness of complete versus partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 system of rat prostatic adenocarcinomas.

W. Ellis, J. Isaacs, 1985, Cancer research.

Modulating paclitaxel bioavailability for targeting prostate cancer.

Simon A. Williams, J. Isaacs, S. Denmeade, 2007, Bioorganic & medicinal chemistry.

Prostate‐specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo

L. Sokoll, H. Lilja, J. Isaacs, 2003, The Prostate.

Thapsigargin analogues for targeting programmed death of androgen-independent prostate cancer cells.

S. Christensen, B. Tombal, J. Isaacs, 1999, Bioorganic & medicinal chemistry.

Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient‐derived xenograft (PDX) models

Yuzhuo Wang, R. Vessella, L. Bubendorf, 2018, The Prostate.

Assessing angiogenic responses induced by primary human prostate stromal cells in a three-dimensional fibrin matrix assay

J. Isaacs, H. Hammers, W. Brennen, 2016, Oncotarget.

A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity.

J. Isaacs, S. Denmeade, S. Aggarwal, 2006, Cancer research.

Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy.

Jun Luo, E. Antonarakis, M. Carducci, 2020, European journal of cancer.

Establishment and characterization of seven dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers

William B. Isaacs, W. Isaacs, J. Isaacs, 1986 .

Advances in Brief CD 44 Is a Metastasis Suppressor Gene for Prostatic Cancer Located on Human Chromosome 11 p 13 '

J. Isaacs, Jin-Tang Dong, A. Gao, 2006 .

Identification of the rat homologue of KAI1 and its expression in dunning rat prostate cancers

J. Barrett, H. Suzuki, J. Isaacs, 1998, The Prostate.

Metastasis suppression by the standard CD44 isoform does not require the binding of prostate cancer cells to hyaluronate.

J. Sleeman, J. Isaacs, A. Gao, 1998, Cancer research.

The R-3327 system of rat prostatic cancers.

J. Isaacs, 1996, Urologic oncology.

Murine monoclonal antibodies reactive with a variety of androgen independent Dunning rat prostate adenocarcinoma sublines also reactive with human prostate adenocarcinoma.

J. Isaacs, A. Tjota, M. ‐. Lee, 1991, The Journal of urology.

Production and significance of TGF-beta in AT-3 metastatic cell line established from the Dunning rat prostatic adenocarcinoma.

J. Isaacs, W. Mckeehan, P. Adams, 1990, Biochemical and biophysical research communications.

Dunning rat prostate tumors and cultured cell lines fail to express human prostate carcinoma‐associated antigens

George L. Wright, J. Isaacs, G. Wright, 1990, The Prostate.

Changes in dihydrotestosterone metabolism associated with the development of canine benign prostatic hyperplasia.

D. S. Coffey, J. Isaacs, 1981, Endocrinology.

The use of multiple variables to predict response to endocrine therapy in carcinoma of the prostate: a preliminary report.

P. Walsh, C. Brendler, J. Isaacs, 1984, The Journal of urology.

Androgenic sensitivity of the gubernaculum testis: evidence for hormonal/mechanical interactions in testicular descent.

P. Walsh, J. Isaacs, J. Elder, 1982, The Journal of urology.

The antiangiogenic agent linomide inhibits tumor necrosis factor‐α secretion via inhibition of its synthesis

J. Isaacs, I. Joseph, 1996, The Prostate.

Rapid in situ hybridization technique for detecting malignant mouse cell contamination in human xenograft tissue from nude mice and in vitro cultures from such xenografts

B. Tombal, J. Isaacs, J. Gao, 1999, The Prostate.

Hormonal Therapy of Prostate Cancer: Limitations in the Total Androgen Ablation Concept

J. Oesterling, D. S. Coffey, J. Isaacs, 1988 .

Inability of complete androgen blockade to increase survival of patients with advanced prostatic cancer as compared to standard hormonal therapy.

T. Senge, J. Isaacs, H. Schulze, 1987, The Journal of urology.

A chicken chorioallantoic membrane assay for the evaluation of the androgen responsiveness of prostatic tissue.

F. Marshall, J. Isaacs, J. Jarow, 1986, The Journal of urology.

Prostate‐specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells

J. Isaacs, B. Slusher, C. Tiffany, 2000, The Prostate.

Introduction: survey of outstanding problems in the management of prostatic cancer.

J. Isaacs, 1991, Cancer surveys.

Anti-angiogenic treatment with linomide as adjuvant to surgical castration in experimental prostate cancer.

J. Isaacs, I. Joseph, J. Vukanović, 1997, The Journal of urology.

798OAR-V7 SPLICE VARIANT AND RESISTANCE TO ENZALUTAMIDE AND ABIRATERONE IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): OVERALL SURVIVAL RESULTS

W. Isaacs, A. Marzo, H. Fedor, 2014 .

Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC

Elizabeth A. Thompson, Jun Luo, J. Hicks, 2022, The Journal of Clinical Investigation.

Characterization of two new enzymatic activities of the rat ventral prostate: 5α-Androstane-3β, 17β-diol 6α-Hydroxylase and 5α-androstane-3β,17β-Diol 7α-Hydroxylase

D. S. Coffey, J. Isaacs, I. McDermott, 1979, Steroids.

The identification and characterization of a new c1903 steroid metabolite in the eat ventral prostate: 5α-androstane-3β, 6α, 17β-triol

D. S. Coffey, J. Isaacs, I. McDermott, 1979, Steroids.

Characterization of two new enzymatic activities of the rat ventral prostate: 5 alpha-androstane-3 beta, 17 beta-diol 6 alpha-hydroxylase and 5 alpha-androstane-3 beta, 17 beta-diol 7 alpha-hydroxylase.

D. S. Coffey, J. Isaacs, I. McDermott, 1979, Steroids.

The identification and characterization of a new C19O3 steroid metabolite in the rat ventral prostate: 5 alpha-androstane-3 beta, 6 alpha, 17 beta-triol.

D. S. Coffey, J. Isaacs, I. McDermott, 1979, Steroids.

Genetic factors and metastatic potential of prostatic cancer.

J. Isaacs, T. Ichikawa, Y. Ichikawa, 1991, Cancer surveys.

Identification of androgen‐responsive genes that are alternatively regulated in androgen‐dependent and androgen‐independent rat prostate tumors

R. Pfundt, J. Schalken, A. V. van Kessel, 2005, Genes, chromosomes & cancer.

Intermediate filament expression and the progression of prostatic cancer as studied in the dunning R‐3327 rat prostatic carcinoma system

J. Schalken, J. Isaacs, F. Ramaekers, 1989, The Prostate.

Characterization of an jY-Methyl-TV-nitrosourea-induced Autochthonous Rat Bladder Cancer Model 1

C. Brendler, G. Steinberg, J. Isaacs, 2006 .

The rat bladder tumor model system RBT resembles phenotypically and cytogenetically human superficial transitional cell carcinoma

J. Schalken, F. Debruyne, J. Isaacs, 1993, Urological Research.

The future of patient-derived xenografts in prostate cancer research

Yuzhuo Wang, J. Schalken, J. Isaacs, 2023, Nature Reviews Urology.

Asporin Restricts Mesenchymal Stromal Cell Differentiation, Alters the Tumor Microenvironment, and Drives Metastatic Progression.

E. Fertig, E. Davicioni, B. Park, 2019, Cancer research.

Mechanistic insights into the inhibition of prostate specific antigen by β‐lactam class compounds

Thomas Lectka, Simon A. Williams, J. Isaacs, 2007, Proteins.

Benzoylphenylurea sulfur analogues with potent antitumor activity.

S. Sukumar, A. Jimeno, M. Hidalgo, 2006, Journal of medicinal chemistry.

Potent and selective peptidyl boronic acid inhibitors of the serine protease prostate-specific antigen.

A. LeBeau, J. Isaacs, S. Denmeade, 2008, Chemistry & biology.

Changes in the metabolism of dihydrotestosterone in the hyperplastic human prostate.

P. Walsh, C. Brendler, J. Isaacs, 1983, The Journal of clinical endocrinology and metabolism.

Thapsigargin induces a calmodulin/calcineurin‐dependent apoptotic cascade responsible for the death of prostatic cancer cells

A. Weeraratna, B. Tombal, J. Isaacs, 2000, The Prostate.

Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancers

J. Isaacs, J. Vukanović, B. Hartley‐åsp, 1995, The Prostate.

Engineering a Prostate-Specific Membrane Antigen–Activated Tumor Endothelial Cell Prodrug for Cancer Therapy

S. Christensen, G. Wilding, P. Nissen, 2012, Science Translational Medicine.

From Plant to Patient: Thapsigargin, a Tool for Understanding Natural Product Chemistry, Total Syntheses, Biosynthesis, Taxonomy, ATPases, Cell Death, and Drug Development.

S. Christensen, P. Nissen, J. Isaacs, 2021, Progress in the chemistry of organic natural products.

Natural products as starting materials for development of second-generation SERCA inhibitors targeted towards prostate cancer cells.

S. Christensen, P. Nissen, C. Olsen, 2006, Bioorganic & medicinal chemistry.

The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin.

Y. Furuya, J. Isaacs, D. Gill, 1994, Cancer research.

The identification and characterization of the c19o3 steroid metabolites of 5α-androstane-3β, 17β-diol produced by the canine prostate: 5α-androstane-3β, 6α, 17β-triol and 5α-androstane-3β, 7α, 17β-triol

D. S. Coffey, J. Isaacs, I. McDermott, 1980, Steroids.

Biochemical methods for predicting metastatic ability of prostatic cancer utilizing the dunning R-3327 rat prostatic adenocarcinoma system as a model.

J. Isaacs, F. Lowe, F. Lowe, 1984, Cancer research.

Why do cells metastasize?

H. Carter, J. Isaacs, 1990, World Journal of Urology.

Metastatic potential prediction by a visual grading system of cell motility: prospective validation in the Dunning R-3327 prostatic adenocarcinoma model.

A. Partin, D. S. Coffey, J. Mohler, 1988, Cancer research.

The aging ACI/Seg versus Copenhagen male rat as a model system for the study of prostatic carcinogenesis.

J. Isaacs, 1984, Cancer research.

Role of androgens in prostatic cancer.

J. Isaacs, 1994, Vitamins and hormones.

Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma.

D. S. Coffey, J. Isaacs, D S Coffey, 1981, Cancer research.

Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system

R. Dahiya, B. O’Malley, J. Isaacs, 2001, Cell Death and Differentiation.

Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration

N. Kyprianou, J. Isaacs, H. English, 1989, The Prostate.

Differences in the effects of estradiol on dihydrotestosterone induced prostatic growth of the castrate dog and rat.

D. S. Coffey, J. Isaacs, R. Ehrlichman, 1981, Investigative urology.

Differential effects of estrogen treatment on canine seminal plasma components.

W. Isaacs, D. S. Coffey, J. Isaacs, 1980, Investigative urology.

Genetic instability coupled to clonal selection as a mechanism for tumor progression in the Dunning R-3327 rat prostatic adenocarcinoma system.

D. S. Coffey, N. Wake, J. Isaacs, 1982, Cancer research.

Biological basis for chemohormonal therapy for prostatic cancer.

N. Kyprianou, J. Isaacs, 1989, Cancer treatment and research.

Abstract 2067: Attacking prostate cancer with a prodrug-doped cellular Trojan horse

J. Karp, J. Isaacs, N. Bhowmick, 2016 .

A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer.

J. Karp, J. Isaacs, N. Bhowmick, 2016, Biomaterials.

A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease.

Simon A. Williams, J. Isaacs, S. Denmeade, 2007, Journal of the National Cancer Institute.

Prostate-specific antigen is a "chymotrypsin-like" serine protease with unique P1 substrate specificity.

A. LeBeau, J. Isaacs, S. Denmeade, 2009, Biochemistry.

Chromosomal changes associated with progression of the Dunning R-3327 rat prostatic adenocarcinoma system.

N. Wake, J. Isaacs, A. Sandberg, 1982, Cancer research.

Relationship between Tumor Size and Curability of Prostatic Cancer by Combined Chemo-Hormonal Therapy in Rats1

J. Isaacs, 2006 .

Relationship between tumor size and curability of prostatic cancer by combined chemo-hormonal therapy in rats.

J. Isaacs, 1989, Cancer research.

Mesenchymal stem cells and the embryonic reawakening theory of BPH

J. Isaacs, W. Brennen, 2018, Nature Reviews Urology.

Resolving the Coffey Paradox: what does the androgen receptor do in normal vs. malignant prostate epithelial cells?

J. Isaacs, 2018, American journal of clinical and experimental urology.

Role of androgen receptor splice variant 7 (AR-V7) in prostate cancer resistance to 2nd generation androgen receptor signaling inhibitors

P. Nelson, Jianfeng Xu, W. Isaacs, 2020, Oncogene.

Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells

A. Partin, W. Isaacs, D. S. Coffey, 1994, The Prostate.

Prostate Cancer Takes Nerve

J. Isaacs, 2013, Science.

Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer

J. Isaacs, S. Denmeade, Xiaohui S. Lin, 1996, The Prostate.

Enhanced Redundancy in Akt and Mitogen-activated Protein Kinase-induced Survival of Malignant versus Normal Prostate Epithelial Cells

J. Isaacs, A. Uzgare, 2004, Cancer Research.

Urological Survey UROLOGICAL ONCOLOGY: PROSTATE CANCER Hedgehog Signalling in Prostate Regeneration, Neoplasia and Metastasis

A. Maitra, P. Beachy, G. Bova, 2005 .

Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells.

J. Isaacs, J. Arnold, J. Gao, 2001, Cancer research.

Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress.

Michael D. Nyquist, P. Nelson, G. Ha, 2020, Cell reports.

Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer

J. Luo, Jun Luo, A. D. De Marzo, 2016, Clinical Cancer Research.

Programmed death of nonproliferating androgen-independent prostatic cancer cells.

N. Kyprianou, J. Isaacs, R. Tucker, 1991, Cancer research.

Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer.

Jianfeng Xu, Jielin Sun, S. Zheng, 2008, Neoplasia.

Expression of a transfected v-Harvey-ras oncogene in a Dunning rat prostate adenocarcinoma and the development of high metastatic ability.

J. Isaacs, B. Treiger, 1988, The Journal of urology.

Tumor‐infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer?

J. Isaacs, A. Meeker, D. Thorek, 2018, The Prostate.

A mammary cancer suppressor gene and its site of action in the rat.

J. Isaacs, John T. Isaacs, 1991, Cancer research.

Transfection Oncogene ras Rat Mammary Cancer Cells following vH-Genetic Instability and the Acquisition of Metastatic Ability by Updated

Kyprianou, Natasha, J. Isaacs, 2006 .

Prostatic Cancer Genetic Factors and Suppression of Metastatic Ability of Updated

J. Isaacs, T. Ichikawa, Y. Ichikawa, 2006 .

Decreased expression of E-cadherin in the progression of rat prostatic cancer.

J. Schalken, M. Takeichi, F. Debruyne, 1992, Cancer research.

Genetic factors and suppression of metastatic ability of prostatic cancer.

J. Isaacs, T. Ichikawa, Y. Ichikawa, 1991, Cancer research.

H‐ras expression, genetic instability, and acquisition of metastatic ability by rat prostatic cancer cells following v‐H‐ras oncogene transfection

J. Schalken, J. Isaacs, T. Ichikawa, 1991, The Prostate.

Genetic instability and the acquisition of metastatic ability by rat mammary cancer cells following v-H-ras oncogene transfection.

N. Kyprianou, J. Isaacs, T. Ichikawa, 1990, Cancer research.

Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study

Jun Luo, E. Antonarakis, M. Carducci, 2015, Science Translational Medicine.

Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells

J. Isaacs, S. Denmeade, D. V. Vander Griend, 2009, Molecular Cancer Therapeutics.

The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells.

A. DeMarzo, J. Isaacs, A. Meeker, 2008, Cancer research.

KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2.

J. Barrett, J. Isaacs, C. Rinker-Schaeffer, 1995, Science.

Localization and physical mapping of the prostate-specific membrane antigen (PSM) gene to human chromosome 11.

J. Isaacs, C. Griffin, C. Rinker-Schaeffer, 1995, Genomics.

Expression of ras proto‐oncogenes in the dunning R3327 rat prostatic adenocarcinoma system

F. S. French, C. Der, J. Isaacs, 1988, The Prostate.

Determination of the number of events required for mammary carcinogenesis in the Sprague-Dawley female rat.

J. Isaacs, 1985, Cancer research.

Rationale Behind Targeting Fibroblast Activation Protein–Expressing Carcinoma-Associated Fibroblasts as a Novel Chemotherapeutic Strategy

J. Isaacs, S. Denmeade, W. Brennen, 2012, Molecular Cancer Therapeutics.

Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer

P. Nelson, Jianfeng Xu, W. Isaacs, 2021, JCI insight.

Albumin-linked prostate-specific antigen-activated thapsigargin- and niclosamide-based molecular grenades targeting the microenvironment in metastatic castration-resistant prostate cancer

J. Isaacs, S. Denmeade, W. Brennen, 2018, Asian journal of urology.

Characterization of an N-methyl-N-nitrosourea-induced autochthonous rat bladder cancer model.

C. Brendler, G. Steinberg, J. Isaacs, 1990, Cancer research.

Defining a common region of deletion at 13q21 in human cancers

H. Frierson, J. C. Barrett, C. Sawyers, 2001, Genes, chromosomes & cancer.

Deletion at 13q21 is associated with aggressive prostate cancers.

H. Frierson, J. Isaacs, Ceshi Chen, 2000, Cancer research.

Oncogene expression in prostate cancer: Dunning R3327 rat dorsal prostatic adenocarcinoma system

F. S. French, J. Isaacs, V. Quarmby, 1988, The Prostate.

Etiology and disease process of benign prostatic hyperplasia

D. S. Coffey, J. Isaacs, D S Coffey, 1989, The Prostate. Supplement.

Dual‐label centromere and telomere FISH identifies human, rat, and mouse cell contribution to Multispecies recombinant urogenital sinus xenografts

A. D. De Marzo, J. Isaacs, A. Meeker, 2009, The Prostate.

The current state of preclinical prostate cancer animal models

W. Hahn, K. Pienta, R. Vessella, 2008, The Prostate.

Angiogenesis and Prostate Cancer

J. Isaacs, I. Joseph, 2001 .

Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment.

J. Isaacs, S. Denmeade, W. Brennen, 2013, Endocrine-related cancer.

Enhanced anti-tumor effects of recombinant human tumor necrosis factor plus VP-16 on metastatic renal cell carcinoma in a xenograft model.

F. Marshall, J. Isaacs, J. Burgers, 1989, The Journal of urology.

Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.

J. Nelson, J. Isaacs, S. Denmeade, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells.

E. Nakakura, C. Strock, G. Bova, 2006, Cancer research.

Bipolar androgen therapy: The rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer

J. Isaacs, S. Denmeade, 2010, The Prostate.

Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer?

Simon A. Williams, J. Isaacs, S. Denmeade, 2007, The Prostate.

Mutational analysis of the TrkA gene in prostate cancer

G. Bova, J. Isaacs, D. George, 1998, The Prostate.

Localization of metastasis suppressor gene(s) for rat prostatic cancer to the long arm of human chromosome 10

M. Oshimura, J. Barrett, J. Isaacs, 1995, Genes, chromosomes & cancer.

Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation.

N. Davidson, N. Kyprianou, J. Isaacs, 1991, Cancer research.

Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug.

J. Isaacs, D. Rosen, S. Denmeade, 2012, Journal of the National Cancer Institute.

Apoptotic pathways in prostate cancer

B. Tombal, J. Isaacs, S. Denmeade, 2001 .

Expression of bcl-2 and the progression of human and rodent prostatic cancers.

John Calvin Reed, S. Krajewski, Y. Furuya, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells.

J. Isaacs, D. V. Vander Griend, I. Litvinov, 2006, Cancer research.

Role of notch-1 and E-cadherin in the differential response to calcium in culturing normal versus malignant prostate cells.

A. D. De Marzo, L. Sokoll, J. Isaacs, 2005, Cancer research.

Prostate cancer — biology of metastasis and its clinical implications

J. Barrett, J. Isaacs, C. Rinker-Schaeffer, 2004, World Journal of Urology.

Reduction of human prostate tumor vascularity by the α1‐adrenoceptor antagonist terazosin

N. Kyprianou, J. Isaacs, S. Jacobs, 2001 .

The current state of preclinical prostate cancer animal models

W. Hahn, K. Pienta, R. Vessella, 2008, The Prostate.

Expression of transforming growth factor-β in the rat ventral prostate during castration-induced programmed cell death

N. Kyprianou, J. Isaacs, 1989 .

Quantification of Mesenchymal Stem Cells (MSCs) at Sites of Human Prostate Cancer

J. Isaacs, Shuangling Chen, S. Denmeade, 2012, Oncotarget.

Detection and Quantification of the Evolution Dynamics of Apoptosis Using the PET Voltage Sensor 18F-Fluorobenzyl Triphenyl Phosphonium

R. Dannals, H. Ravert, J. Frost, 2009, Journal of Nuclear Medicine.

A Phase I Study to Assess the Safety and Cancer‐Homing Ability of Allogeneic Bone Marrow‐Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer

J. Karp, A. Partin, A. D. De Marzo, 2019, Stem cells translational medicine.

Human prostate cancer initiating cells isolated directly from localized cancer do not form prostaspheres in primary culture

J. Isaacs, Shuangling Chen, Lorenzo Principessa, 2012, The Prostate.

Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells.

C. Drake, A. D. De Marzo, J. Isaacs, 2009, Proceedings of the National Academy of Sciences of the United States of America.

Identification of a cellular receptor for transforming growth factor-beta in rat ventral prostate and its negative regulation by androgens.

N. Kyprianou, J. Isaacs, 1988, Endocrinology.

Establishing a cryopreservation protocol for patient‐derived xenografts of prostate cancer

P. Nelson, Hong Wang, D. Murphy, 2019, The Prostate.

The what, when, and why of human prostate cancer xenografts

J. Isaacs, W. Brennen, John T. Isaacs, 2018, The Prostate.

The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer

J. Isaacs, 2010, Expert opinion on investigational drugs.

Open Access Research

Johan Vallon-Christersson, J. Vallon-Christersson, T. Leanderson, 2022 .

Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer

K. Pienta, D. Qian, A. D. De Marzo, 2021, Cancer Research.

Androgen receptor (AR) suppresses normal human prostate epithelial cell proliferation via AR/β‐catenin/TCF‐4 complex inhibition of c‐MYC transcription

J. Isaacs, L. Antony, S. Dalrymple, 2014, The Prostate.

Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells

C. Drake, A. D. De Marzo, J. Isaacs, 2006, Proceedings of the National Academy of Sciences.

Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer

J. Karp, J. Isaacs, B. Simons, 2020, Molecular Cancer Therapeutics.

Effect of pentosan, a novel cancer chemotherapeutic agent, on prostate cancer cell growth and motility

K. Pienta, W. Isaacs, D. S. Coffey, 1992, The Prostate.

Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint

A. Partin, M. Carducci, J. Isaacs, 2007, Cancer biology & therapy.

Serial bipolar androgen therapy (sBAT) using cyclic supraphysiologic testosterone (STP) to treat metastatic castration-resistant prostate cancer (mCRPC).

J. Isaacs, S. Denmeade, W. Brennen, 2019, Annals of translational medicine.

Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.

K. Kihara, J. Isaacs, J. Ishioka, 2007, The Prostate.

Prostate cancer: potential targets of anti-proliferative and apoptotic signaling pathways.

J. Isaacs, A. Uzgare, John T Isaacs, 2005, The international journal of biochemistry & cell biology.

Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation

R. Hales, M. Hedayati, T. DeWeese, 2016, Clinical Cancer Research.

Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587).

N. Neff, J. Isaacs, A. M. Camoratto, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Prostatic cancer: an age-old problem.

J. Isaacs, 1993, Advances in experimental medicine and biology.

Genomic organization of the human KAI1 metastasis-suppressor gene.

W. Isaacs, J. Barrett, J. Isaacs, 1997, Genomics.

BipolarAndrogenTherapy:TheRationale forRapid Cyclingof SupraphysiologicAndrogen/Ablation inMen

J. Isaacs, S. Denmeade, 2010 .

Rapid selection of mesenchymal stem and progenitor cells in primary prostate stromal cultures

J. Isaacs, W. Brennen, L. N. Kisteman, 2016, The Prostate.

Evaluation of Win 49,596, a novel steroidal androgen receptor antagonist, in animal models of prostate cancer

J. Isaacs, J. Lamb, M. Wolf, 1991, The Prostate.

Stabilizing Androgen Receptor in Mitosis Inhibits Prostate Cancer Proliferation

J. Isaacs, D. V. Vander Griend, I. Litvinov, 2007, Cell cycle.

Location of KAI1 on the short arm of human chromosome 11 and frequency of allelic loss in advanced human prostate cancer

J. Barrett, J. Isaacs, Jin-Tang Dong, 1997, The Prostate.

Development of hormone refractory tumors: adaption versus clonal selection.

J. Isaacs, H. Schulze, 1990, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Comparative aspects of prostatic growth and androgen metabolism with aging in the dog versus the rat.

J. Isaacs, S. Berry, 1984, Endocrinology.

Inheritance of a genetic factor from the Copenhagen rat and the suppression of chemically induced mammary adenocarcinogenesis.

J. Isaacs, John T. Isaacs, 1988, Cancer research.

Proaerolysine contenant des sequences d'activation de protease et procedes destines au traitement du cancer de la prostate

J. Isaacs, S. Denmeade, J. Buckley, 2002 .

Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment

T. Leanderson, J. Isaacs, D. Rosen, 2014, Oncotarget.

The “Infectious” Nature of Human Prostate Cancer: A Cautionary Note

J. Isaacs, K. Sfanos, 2011, Oncotarget.

Apoptosis in hormone-responsive malignancies.

N. Davidson, J. Isaacs, S. Denmeade, 1997, Advances in pharmacology.

Molecular and cellular markers for metastatic prostate cancer

W. Isaacs, J. Isaacs, C. Rinker-Schaeffer, 1993, Cancer Metastasis Review.

Development and characteristics of the available animal model systems for the study of prostatic cancer.

J. Isaacs, J T Isaacs, John T. Isaacs, 1987, Progress in clinical and biological research.

Programmed cell death as a new target for prostatic cancer therapy.

N. Kyprianou, J. Isaacs, L. Davis, 1991, Cancer surveys.

Oncogene expression in prostate cancer

J. Schalken, W. V. D. Van de Ven, F. Debruyne, 1991, World Journal of Urology.

Rationale for bipolar androgen therapy (BAT) for metastatic prostate cancer

J. Isaacs, S. Denmeade, W. Brennen, 2017, Cell cycle.

DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer.

J. Isaacs, D. V. Vander Griend, Jason M. D'Antonio, 2009, Endocrine-related cancer.

Androgen receptor outwits prostate cancer drugs

W. Isaacs, J. Isaacs, William B Isaacs, 2004, Nature Medicine.

Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)‐activated prodrug in murine xenograft models of human cancer

G. Netto, J. Isaacs, D. Rosen, 2014, The Prostate.

Engineering Enzymatically Activated “Molecular Grenades” for Cancer

J. Isaacs, S. Denmeade, 2012, Oncotarget.

The SERCA pump as a therapeutic target: Making a “smart bomb” for prostate cancer

J. Isaacs, S. Denmeade, 2005, Cancer biology & therapy.

Inhibition of caspase activity does not prevent the signaling phase of apoptosis in prostate cancer cells

B. Tombal, J. Isaacs, S. Denmeade, 1999, The Prostate.

Cellular Origin of Androgen Receptor Pathway-Independent Prostate Cancer and Implications for Therapy.

J. Isaacs, W. Brennen, 2017, Cancer cell.

Mipsagargin: The Beginning-Not the End-of Thapsigargin Prodrug-Based Cancer Therapeutics.

S. Christensen, J. Isaacs, S. Denmeade, 2021, Molecules.

Prostatic growth effects of rat urogenital sinus and human prostatic tissue in the rat

J. Isaacs, Jonathan P. Jarow, 1989, The Prostate.

Conversion of Androgen Receptor Signaling From a Growth Suppressor in Normal Prostate Epithelial Cells to an Oncogene in Prostate Cancer Cells Involves a Gain of Function in c-Myc Regulation

J. Isaacs, D. V. Vander Griend, I. Litvinov, 2014, International journal of biological sciences.

Development of androgen-independent tumor cells and their implication for the treatment of prostatic cancer

N. Kyprianou, J. Isaacs, 2004, Urological Research.

Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers.

J. Isaacs, J. Vukanović, Jasminka Vukanović, 1995, Cancer research.

Pharmacologic Exhaustion of Suppressor Cells with Tasquinimod Enhances Bacterial Clearance during Tuberculosis

W. Bishai, T. Leanderson, J. Isaacs, 2019, American journal of respiratory and critical care medicine.

Activation of programmed (apoptotic) cell death for the treatment of prostate cancer.

J. Isaacs, S. Denmeade, 1996, Advances in pharmacology.

Proliferation Independent Activation of Programmed Cell Death as a Novel Therapy for Prostate Cancer

Y. Furuya, J. Isaacs, P. Lundmo, 1994 .

Antiangiogenic effects of the quinoline-3-carboxamide linomide.

A. Passaniti, R. Traystman, J. Isaacs, 1993, Cancer research.

New principles in the management of metastatic prostatic cancer.

J. Isaacs, 1985, Progress in clinical and biological research.

There are gremlins in prostate cancer

J. Isaacs, W. Brennen, L. Sena, 2022, Nature Cancer.

Development of prostate cancer treatment: The good news

J. Isaacs, S. Denmeade, 2004, The Prostate.

of Prostatic Epithelial Cells Androgen-stimulated Growth during Malignant Transformation Conversion from a Paracrine to an Autocrine Mechanism of

J. Isaacs, J. Arnold, Jin Gao, 2013 .

New strategies for the medical treatment of prostate cancer

J. Isaacs, 2005, BJU international.

Development of an androgen receptor-null model for identifying the initiation site for androgen stimulation of proliferation and suppression of programmed (apoptotic) death of PC-82 human prostate cancer cells.

J. Isaacs, J. Gao, Jin Gao, 1998, Cancer research.

CEP‐751 inhibits trk receptor tyrosine kinase activity in vitro and exhibits anti‐tumor activity

N. Neff, J. Isaacs, A. Maroney, 1997, International journal of cancer.

Androgen receptor splice variant, AR-V7, and resistance to enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC).

Hao Wang, W. Isaacs, Jun Luo, 2014 .

Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy (Science Translational Medicine)

S. Christensen, G. Wilding, P. Nissen, 2012 .

Epidemiologic evidence regarding predisposing factors to prostate cancer

H. Carter, J. Isaacs, B. Carter, 1990, The Prostate.

In Reply

J. Karp, A. Partin, A. D. De Marzo, 2019, Stem cells translational medicine.

Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.

J. Isaacs, A. Schally, K. Szepesházi, 1992, Cancer research.

5Alpha-reductase inhibitors and the treatment of benign prostatic hyperplasia

J. Isaacs, 1993 .

Changes in dihydrotestosterone metabolism and the development of benign prostatic hyperplasia in the aging beagle.

J. Isaacs, John T. Isaacs, 1983, Journal of steroid biochemistry.

Response of rat and human prostatic cancers to the novel 5 alpha-reductase inhibitor, SK&F 105657.

J. Isaacs, R. Johnson, J. Lamb, 1992, The Prostate.

Glyceraldehyde-3-phosphate dehydrogenase expression during apoptosis and proliferation of rat ventral prostate.

A. Sawa, J. Isaacs, D. Epner, 1999, Biology of reproduction.

Etiology of benign prostatic hyperplasia.

J. Isaacs, 1994, European urology.

Androgen withdrawal fails to induce detectable tissue hypoxia in the rat prostate

M. Hedayati, T. DeWeese, Yonggang Zhang, 2014, The Prostate.

Requirements for an idealized animal model of prostatic cancer.

D. S. Coffey, J. Isaacs, 1980, Progress in clinical and biological research.

Advances and controversies in the study of programmed cell death/apoptosis in the development of and therapy for cancer.

J. Isaacs, 1994, Current opinion in oncology.

Lessons learned about prostatic transformation from the age-related methylation of 5α-reductase type 2 gene.

J. Isaacs, 2015, The American journal of pathology.

597: Requirement for Autonomous Hedgehog Signal Response in Prostate Cancer Metastases

P. Beachy, G. Bova, J. Isaacs, 2004 .

Genetic factors and suppression of metastatic ability of v-Ha-ras-transfected rat mammary cancer cells.

J. Isaacs, T. Ichikawa, Y. Ichikawa, 1992, Proceedings of the National Academy of Sciences of the United States of America.

Mapping of metastasis suppressor genes for prostate cancer by microcell-mediated chromosome transfer.

M. Oshimura, J. Barrett, H. Suzuki, 2000, Asian journal of andrology.

Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC

Elizabeth A. Thompson, Jun Luo, J. Hicks, 2022, The Journal of clinical investigation.

Activationof Latent Protease Functionof Pro-HK2,

J. Isaacs, Saeed R. Khan, R. Denmeade, 2022 .

Establishing a cryopreservation protocol for patient‐derived xenografts of prostate cancer

Hong Wang, D. Murphy, M. Frydenberg, 2019, The Prostate.

Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia.

A. Borkowski, A. Partin, N. Kyprianou, 1999, The Journal of urology.

Rationale Behind Targeting Fibroblast Activation Protein–Expressing Carcinoma-Associated Fibroblasts as a Novel Chemotherapeutic Strategy

J. Isaacs, S. Denmeade, W. Brennen, 2012, Molecular Cancer Therapeutics.

Engineering a Prostate-Specific Membrane Antigen–Activated Tumor Endothelial Cell Prodrug for Cancer Therapy

S. Christensen, G. Wilding, P. Nissen, 2012, Science Translational Medicine.

Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts

T. DeWeese, Haoming Zhou, J. Isaacs, 2012, The Prostate.

ResearchTasquinimod ( ABR-215050 ) , a quinoline-3-carboxamide anti-angiogenic agent , modulates the expression of thrombospondin-1 in human prostate tumors

J. Vallon-Christersson, T. Leanderson, J. Isaacs, 2015 .

Angiogenesis and Prostate Cancer

J. Isaacs, I. Joseph, 2001 .

Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation

R. Hales, M. Hedayati, T. DeWeese, 2016, Clinical Cancer Research.

Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment

T. Leanderson, J. Isaacs, Anders Olsson, 2014, Oncotarget.

The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer

J. Isaacs, 2010, Expert opinion on investigational drugs.

Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells

J. Isaacs, S. Denmeade, L. Antony, 2009, Molecular Cancer Therapeutics.

Enzymatically active prostate‐specific antigen promotes growth of human prostate cancers

Simon A. Williams, J. Isaacs, S. Denmeade, 2011, The Prostate.

Abstract 2076: Albumin-linked proaerolysin based molecular grenades: A systemic therapeutic for disseminated castration resistant prostate cancer

Freddie L. Pruitt, J. Isaacs, D. Rosen, 2016 .

Death of PC-82 Human Prostate Cancer Cells Proliferation and Suppression of Programmed ( Apoptotic ) Identifying the Initiation Site for Androgen Stimulation of Development of an Androgen Receptor-null Model for Updated

J. Isaacs, Jin Gao, 2006 .

Biochemical methods for predicting metastatic ability of prostatic cancer utilizing the dunning R-3327 rat prostatic adenocarcinoma system as a model.

J. Isaacs, F. Lowe, 1984, Cancer research.

Prostate Cancer following Androgen Ablation Programmed Cell Death during Regression of PC-82 Human Updated

N. Kyprianou, J. Isaacs, H. English, 2006 .

DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer.

J. Isaacs, Jason M. D'Antonio, Donald J. Vander Griend, 2009, Endocrine-related cancer.

Prostatic cancer: an overview

J. Isaacs, 1993, Cancer and Metastasis Reviews.

Animal models in the study of prostatic cancer

D. S. Coffey, J. Isaacs, 1979 .

Mipsagargin: The Beginning—Not the End—of Thapsigargin Prodrug-Based Cancer Therapeutics

S. Christensen, J. Isaacs, S. Denmeade, 2021, Molecules.